English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA first-of-its kind drug for prostate cancer, an ancient retrovirus that may drive aggressive brain cancer, disparities in endometrial cancer rates among Black women, a new trial seeking answers for higher rates of aggressive prostate and breast cancer in Black men and women, and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center.
Tag: Cisplatin
In preclinical study, Sylvester researchers target treatment-resistant prostate cancer with oral chemotherapy that works 2 ways
Researchers at Sylvester Comprehensive Cancer Center have developed a first-of-its-kind, orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells. The compound – Platin-L – works in two ways, breaking down a process that malignant prostate cancer cells use to fuel their growth, and delivering cisplatin directly into treatment-resistant cancer cells.
Pharmacologist: Cancer drug shortage is delaying lifesaving treatments
This year, an estimated 2 million Americans will be diagnosed with cancer. Now, a New York Institute of Technology pharmacology expert contends that these patients’ realities could grow increasingly harsher, as a monthslong shortage of chemotherapy drugs continues. Low supplies of…
NCCN Releases Statement Addressing Ongoing Chemotherapy Shortages; Shares Survey Results Finding More than 90% of Cancer Centers are Impacted
National Comprehensive Cancer Network’s Department of Policy and Advocacy calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin; two medications that are used in combination to cure many types of cancer.
Chemotherapy Drug Increases Kidney Injury in Mouse Model of Lung Cancer
Article title: Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity Authors: Andrew Orwick, Sophia M. Sears, Cierra N. Sharp, Mark A. Doll, Parag P. Shah, Levi J. Beverly, Leah J. Siskind From the authors: “This…
Wayne State receives $1.7 million NIH award to understand and address ototoxic side effects of anti-cancer drug
Wayne State’s Dr. Jamesdaniel received a $1.7 million NIH grant to study cisplatin, a drug that is prescribed to 10 to 20% of cancer patients that causes hearing loss in up to 80% treated with the drug.